LarvolClinCancer Trial Results
Trials Conferences Kaplan-Meier Plot Forest Plot Influencers
menu
Back

ESMO Plenary Mar 2022 - ESMO Virtual Plenaries: March 2022

Mar 16 - Mar 18, 2022 | LuganoSwitzerland

LARVOL is not affiliated with ESMO Virtual Plenaries: March 2022 and all trademarks, logos, and brand names are property of their respective owners

Condition
Stage
Treatment
Setting
Biomarker
Trial Name/ID

Showing 3 abstracts linked to Trials

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

  • OlympiA
    Plenary

Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

  • KEYNOTE-091
    Plenary

Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

  • SIENDO
    Plenary

Copyright © LARVOL 2023. All rights reserved.

  • Privacy Policy
  • Terms of Service
clear

Trials

Conferences

Kaplan-Meier Plot

Forest Plot

Influencers

Feedback

Privacy Policy Terms of Service